Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 19 Mar 2018
At a glance
- Drugs RIX 4414 (Primary)
- Indications Rotavirus infections
- Focus Pharmacodynamics; Registrational
- Acronyms ROTA-081
- Sponsors GlaxoSmithKline
- 15 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 09 Nov 2017 Planned End Date changed from 16 Nov 2018 to 25 Dec 2018.
- 09 Nov 2017 Planned primary completion date changed from 13 Jul 2018 to 28 Jul 2018.